贝克曼革命式的诊断分子诊断与精益流程和降低样品周转时

StephenW

Product News: Beckman Coulter Diagnostics Revolutionises Molecular Diagnostics with LEAN Workflow and Reduced Sample Turn-around Times
24 Apr 2015

LinkedInFacebookTwitterEmailMore

Beckman Coulter Diagnostics will be showcasing its revolutionary DxN VERIS Molecular Diagnostics System* on Stand 253 at the 25th European Congress of Clinical Microbiology and Infectious Diseases, in Copenhagen, Denmark. The CE-marked system is now available with CE-marked assays for Human Cytomegalovirus (CMV) and Hepatitis B Virus (HBV)*. Additional assays for Human Immunodeficiency Virus (HIV-1) and Hepatitis C Virus (HCV) have been submitted for CE-mark certification*. Further menu expansion will follow with many other assays currently in development.

“The DxN VERIS Molecular Diagnostics System is designed to revolutionise the clinical laboratory with LEAN workflow and improved sample turn-around time,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics. “The system’s true single sample random access empowers laboratories to perform viral load tests whenever they want, at a time that suits them—ultimately helping physicians make faster clinical decisions and positively impacting patients.”

The DxN VERIS Molecular Diagnostics System assays are supplied in a unique, single cartridge system that are cost- and time-effective. Unlike traditional batch-plate systems, there are no empty wells, so the DxN VERIS Molecular Diagnostics System reduces wastage and consumable costs. With the DxN VERIS Molecular Diagnostics System, all necessary consumables and reagents are on-board, so there is no lengthy set-up and tests can be up and running in less than 10 minutes.

“With rapid processing, the DxN VERIS Molecular Diagnostics System’s short run-times ensure that results are delivered to physicians as quickly as possible,” Richard Creager, senior vice president, Molecular Diagnostics Business Unit, and chief scientific officer at Beckman Coulter Diagnostics. “By consolidating DNA extraction, amplification and detection within a single instrument, we have significantly reduced manual intervention and are enabling labs to go from a sample to an answer in just 70 minutes.”
- See more at: http://www.selectscience.net/pro ... X1Hq6.OlPF1lOn.dpuf

StephenW

产品资讯：贝克曼革命式的诊断分子诊断与精益流程和降低样品周转时间
2015年4月24日

LinkedInFacebookTwitterEmailMore

贝克曼库尔特诊断将展示其革命性的DXN VERIS分子诊断系统*展位上，在253临床微生物学和传染病的第25届欧洲议会，在丹麦首都哥本哈根。在CE标志的系统现在可提供CE标记测定人类巨细胞病毒（CMV）和乙型肝炎病毒（HBV）*。已提交的CE-mark认证的附加试验人类免疫缺陷病毒（HIV-1）和丙型肝炎病毒（HCV）所*。进一步扩展菜单将遵循与其他许多试验目前正在开发中。

“该DXN VERIS分子诊断系统的设计带来革命性的临床实验室精益的工作流程和周转时间提高了样品，”ARND Kaldowski，总裁，Beckman Coulter公司诊断说。 “该系统的真正的单一样本随机存取授权的实验室进行病毒载量测试时，他们想要的，在适合时间他们，最终帮助医生做出更快的临床决策和积极影响的病人。”

该DXN VERIS分子诊断系统测定是在提供一个独特的单墨盒系统，它是成本和时间效益。不同于传统的批量板系统，没有空井，所以DXN VERIS分子诊断系统减少浪费和耗材成本。与DXN VERIS分子诊断系统，所有必要的耗材和试剂车载，所以没有冗长的设置和测试，可以达到在不到10分钟的运行。

“有了快速处理，对DXN VERIS分子诊断系统的短期运行时间确保结果尽快交付给医生，”理查德Creager，高级副总裁，分子诊断业务部和首席科学官贝克曼诊断。 “通过整合DNA提取，扩增和检测在一个单一的工具，我们已经显著减少人工干预，并且使实验室从样品去一个答案在短短的70分钟。”
- 在查看更多： http://www.selectscience.net/pro ... X1Hq6.OlPF1lOn.dpuf